Voyager Therapeutics (VYGR) Non Operating Income (2015 - 2026)

Voyager Therapeutics has disclosed Non Operating Income across 12 years of filings, most recently posting $435000.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at $435000.0, down 88.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.3 million (up 340.16% YoY), and the FY2025 annual result was $12.3 million, up 1872.19% from the prior year.
• Non Operating Income came in at $435000.0 for Q1 2026 at Voyager Therapeutics, down from $11.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $11.7 million in Q4 2023 to a low of -$13.9 million in Q4 2024.
• The 5-year median for Non Operating Income is $1.9 million (2023), against an average of $2.2 million.
• Across the five-year window, Non Operating Income soared 5912.9% in 2023 and plunged 218.86% in 2024, its largest moves.
• Voyager Therapeutics' Non Operating Income stood at $1.8 million in 2022, then surged by 562.58% to $11.7 million in 2023, then slumped by 218.86% to -$13.9 million in 2024, then jumped by 179.11% to $11.0 million in 2025, then slumped by 96.05% to $435000.0 in 2026.
• The last three Non Operating Income figures came in at $435000.0 (Q1 2026), $11.0 million (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.